NeoGenomics, Inc.
NEOHealthcareNASDAQDiagnostics & Research · Last scanned Jun 3, 2026
Scan Results
Daily timeframeNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The $1.32B market capitalization puts NEO squarely in small-cap range for its industry. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Market Cap
$1.32B
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
27.76
EPS (TTM)
$-0.77
EPS (Fwd)
$0.36
ROE
-11.6%
ROA
-2.6%
Cash
$146.1M
Total Debt
$408.5M
Free CF
$33.2M
52W Change
37.1%
Annual Financials
Cash vs Debt
NeoGenomics, Inc. carries $408.5M in total debt against $146.1M in cash reserves — debt is roughly 2.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $33.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -11.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $509.7M (2022) to $727.3M (2025), reflecting a 43% increase over the period.
With a beta above 1.5, NEO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NEO.